Reimagine the health of your patients by targeting the gut microbiome

Using cutting-edge technology and microbiome science, Pendulum has identified proprietary strains, like Akkermansia muciniphila, that increase synthesis of health-promoting postbiotics and strengthen gut barrier integrity.

In a clinical trial, Pendulum’s flagship product Pendulum Glucose Control, a blend of Akkermansia muciniphila and four other high-potency bacterial strains, was shown to help lower A1C and post-meal glucose spikes in people with type 2 diabetes taking metformin.

Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s clinically-studied strains, is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.

Want to become a Pendulum partner?

We’d love to share how our partnership program works.

Enhance patient care

Improve the health of your patients, receive exclusive discounts for your patients, connect with other thought leaders.

Continuing education credits

Become a microbiome expert while earning free continuing education units!

Increase your exposure

Interact and network with other microbiome experts and expand your network across the nation.

Learn more about becoming a partner

Apply Now

Our strains deserve a spotlight

Precision matters. Meet the powerful ingredients behind Pendulum’s next-generation probiotics.

Akkermansia muciniphila

The gut-lining builder

A highly targeted strain that can only be found in Pendulum Glucose Control & Akkermansia products. People with Type 2 diabetes are shown to be deficient in Akkermansia, which can be associated with healthy weight management.

Clostridium butyricum

The digestive health & butyrate-producer

Naturally found in the human GI tract, this strain is named for its ability to produce high amounts of the short-chain fatty acid butyrate. It has been associated with digestion support and immune health.

Clostridium beijerinckii

The other butyrate producer

This novel strain produces the short-chain fatty acid butyrate, which helps the body process sugar.

Anaerobutyricum hallii

Another butyrate producer

Have we mentioned the importance of butyrate? This is another strain known to produce butyrate, helping the body process sugar and heal the lining of the gut.

Bifidobacterium infantis

The digestive health booster

Breaks down a range of foods and produces the intermediate molecules that are used by the three butyrate-producing strains above. This strain helps maintain a healthy GI tract and helps alleviate IBS symptoms.

Chicory inulin

The probiotic power source for blood sugar

A soluble fiber that can travel to the lower gut and stimulate the growth of the probiotics above. Studies have shown that inulin helps lower fasting blood sugar, reduces fasting insulin, and improves good cholesterol in people with type 2 diabetes.

Mechanism of Action

Synthesis of health-promoting postbiotics

Pendulum’s precise anaerobic strains restore the body’s natural capability to produce the postbiotic butyrate. Butyrate binds to specific receptors within the gut mucosa and stimulates the release of glucagon-like peptide-1 (GLP-1), which is an incretin hormone. GLP-1 is deficient in people with impared glucose tolerance and Type 2 diabetes, which contributes to hyperglycemia.

The benefits of GLP-1 go beyond diabetes. Balancing blood sugar is vital to health. In people not living with type 2 diabetes, GLP-1

Promotes satiety and reduces appetite
Improves glucose control
Boosts metabolic health

Strengthen gut barrier and reduce permeability

Thinning in the large intestine mucin layer can lead to the development of gut dysbiosis, allowing pathogens and toxins to seep into systemic circulation. Pendulum probiotic formulations are uniquely able to improve the gut ecosystem and fuel fortification of the protective mucin layer, strengthening intestinal integrity.

The primary function of Akkermansia muciniphila, one of Pendulum’s proprietary strains, is to support healthy mucin layer turnover in the intestines, and thus strengthen the intestinal lining. Furthermore, this process releases short chain fatty acids such as acetate and propionate, that support the abundance and diversity of other health-promoting microorganisms in the gut.

A1C Reduction 1

-0.6%

Post Prandial Glucose spike reduction 2

-32.5%

Our clinical trial.

In a double-blind, placebo-controlled nutrition study, Pendulum Glucose Control was demonstrated to:

• Be safe and well-tolerated by study participants

• Have a statistically and clinically significant impact on A1C and post-meal blood-glucose spikes

Clinical trial included participants taking metformin, compared to placebo.
1. Subjects administered the Pendulum Glucose Control formulation had significantly improved A1C compared to placebo.
2. Observed reduction in glucose AUC is expected to increase time spent within the healthy glucose range (TIR70-180) during continuous glucose monitoring. Increases in TIR70-180 strongly correlate to reductions in A1C and reduced risk for complications in T2D.

Read now

Our studies

Increased butyrate and UCDA during probiotic intervention in humans with type 2 diabetes

Read Study

Improvements to Postprandial Glucose Control in Subjects with Type 2 Diabetes (T2D)

Read Study

Review: Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease

Read Study

White Paper: An in-depth profile of the gut commensal, Akkermansia muciniphila

Read Study

Resources for you and your practice

Product Factsheets

Comprehensive Overview

Akkermansia

GI Repair

Pendulum Glucose Control

Science starts with collaboration

From Ph.D.s to MDs to RDs, we’re surrounded by smarts.

We’ve partnered with top doctors, researchers, and scientists from pretty impressive institutions—like Stanford, Johns Hopkins, UCLA, Mayo Clinic, and the American Diabetes Association.

Our medical research team is led by Chief Medical Officer Orville Kolterman, MD. Dr. Kolterman is a diabetes expert and previous Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early-stage development through trials to market.

Together with Dr. Kolterman, we work with leading diabetes professionals to ensure our products deliver results and meet the highest standards of efficacy and safety.